RxSight Q2 FY26 net loss widens 2.6% to $12.1 million; revenue rises 0.3% to $33.7 million
Reuters2026/08/05 21:24- RxSight posted Q2 revenue of $33.74 million, up 0.3% year over year, as a $6.5 million license fee offset weaker product sales.
- Operating loss narrowed to $13.77 million; net loss widened to $12.1 million, while product gross margin fell 3.7 percentage points to 71.2%.
- Product sales slid 19% to $27.24 million on lower LDD and LAL unit volumes, with LDD revenue dropping to $1.34 million from fewer placements.
- LDDs sold fell to 11 from 40, while LALs sold eased to 24,917; the installed base rose to 1,166 at quarter-end.
- RxSight named Aziz Mottiwala CEO effective July 20, added him to the board, and signed a collaboration with Alcon that generated the $6.5 million license revenue.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic's annualized revenue in July reportedly exceeded $65 billions, more than seven times higher than at the end of last year.
Last Friday, it was reported that Anthropic achieved preliminary revenue of over 11.5 billions USD in Q2, representing a year-on-year increase of nearly 14 times, and has already reached profitability on an adjusted operating income basis.
Vamos publishes presentation for Aug. 17 extraordinary shareholder meeting
Zevra Therapeutics Chief Legal & Compliance Rahsaan Thompson sells 42,666 shares for $474,781.44
Crypto prices
More
